Renaissance Capital logo

CollPlant Holdings Direct listing, Nasdaq: CLGN

Clinical-stage biotech focused on regenerative medicine for tissue repair.

Industry: Health Care

First Day Return: n/a

Industry: Health Care

We are a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. Our products and product candidates are based on our recombinant human collagen (rhCollagen) that is produced with our proprietary plant based genetic engineering technology. Our products and product candidates address indications for the diverse fields of tissue repair, aesthetics and organ manufacturing, and, we believe, are ushering in a new era in regenerative and aesthetic medicine. Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, CollPlant, our wholly-owned subsidiary, entered into a license agreement with LB, a public benefit corporation and wholly-owned subsidiary of United Therapeutics Corporation, pursuant to which CollPlant and LB are collaborating in 3D bio-printing development of engineered lungs or lung substitutes, and LB is using our BioInks in order to manufacture 3D bioprinted lungs for transplant in humans.
more less
IPO Data
IPO File Date 10/21/2016
Offer Price $9.00
Price Range $6.23 - $6.23
Offer Shares (mm) 0.0
Deal Size ($mm) $0
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/30/2020
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $0
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Ness-Ziona, Israel
Founded 2004
Employees at IPO 37
Website www.collplant.com

CollPlant Holdings (CLGN) Performance